SERPINA1 and benign neoplasm: As early as 1978, Rostenberg et al. found statistically significant differences in alpha1-antitrypsin (alpha1-AT) glycosylation levels between patients with lung, prostate, and gastrointestinal cancers and control patients with benign tumors [12].